Log in

T2016-002 Nivolumab

Protocol Opened: 23 April 2019

Study Contact:

  • Protocol Chair: Anupam Verma, MD
  • Protocol Vice Chair: Deepa Bhojwani, MD
  • Protocol Vice Chair: Nobuko Hijiya, MD

CURRENT STUDY DOCUMENTS

T2016-002 Protocol Amendment Version 2 Date 03 September 2021 T2016-002 Protocol Amendment Version 2 Date 03 September 2021
T2016-002 Amendment Version 2 Sample Consent T2016-002 Amendment Version 2 Sample Consent
T2016-002 Eligibility Worksheet Version Date 03 September  2021 T2016-002 Eligibility Worksheet Version Date 03 September 2021
T2016-002 Research Monitoring Plan T2016-002 Research Monitoring Plan
 IND 140029-FDA Approval Letter  IND 140029-FDA Approval Letter 
T2016-002 Investigator WebEx Training Slides T2016-002 Investigator WebEx Training Slides 
T2016-002  Investigator Brochure v.20 T2016-002 Investigator Brochure v.20
 T2016-002 Investigator Training Log T2016-002 Investigator Training Log
Quality of Life Questionnaires
Correlative Studies
Enrollment & Drug Ordering Forms
Roadmap, Weekly Reports & eCRF Guidelines
Adverse Events & DLT
Data Safety Monitoring & Progress Reports
BMS Pregnancy Surveillance Form
Previous Protocol Documents
TACL Memos
External SUSARS from BMS